Analysis of CYP2D6 substrate interactions by computational methods

被引:38
作者
Ito, Yuko [1 ]
Kondo, Hiroki [1 ]
Goldfarb, Peter S. [2 ]
Lewis, David F. V. [2 ]
机构
[1] Kyushu Inst Technol, Dept Biosci & Bioinformat, Iizuka, Fukuoka 8208502, Japan
[2] Univ Surrey, Sch Biomed & Mol Sci, Guildford GU2 7XH, Surrey, England
关键词
cytochrome P450 (CYP); automated docking; homology modelling; molecular dynamics (MD); site-directed mutagenesis;
D O I
10.1016/j.jmgm.2007.07.004
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cytochrome P450 CYP2D6 is involved in the oxidation of well over 150 drugs and, in general, those which contain a basic nitrogen atom in the molecule. To clarify how the residues of CYP2D6 are utilized for orientating a wide range of its specific substrates and distinguishing them from a variety of other organic compounds, docking studies by AutoDock and molecular dynamics (MD) simulations were conducted. Specific ligands were docked to both the homology model and crystal structures optimally to estimate the site of reaction on the ligand molecule and the binding energy for the complex, which were generally in good agreement with the experimental data. MD simulation for the CYP2D6-propranolol complex was then carried out to reveal the amino acid residues interacting with the substrate at the active site. Phe-120, Glu-216, Asp-301, and Phe-483 are identified as the substrate-binding residues in agreement with previously reported site-directed mutagenesis data and the crystal structure reported recently (PDB code: 2F9Q). As well as these residues, our theoretical prediction suggests that Phe-219 and Glu-222 are also important residues for mediating oxidation of substrates, especially propranolol. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:947 / 956
页数:10
相关论文
共 60 条
[1]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[2]   Protein structure prediction and structural genomics [J].
Baker, D ;
Sali, A .
SCIENCE, 2001, 294 (5540) :93-96
[3]   Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders [J].
Bertilsson, L ;
Dahl, ML .
CNS DRUGS, 1996, 5 (03) :200-223
[4]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[5]  
CASE DA, 2002, AMBER, V7
[6]   Pharmacogenetics of the cytochromes P450 [J].
Daly, AK .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (16) :1733-1744
[7]   Nomenclature for human CYP2D6 alleles [J].
Daly, AK ;
Brockmoller, J ;
Broly, F ;
Eichelbaum, M ;
Evans, WE ;
Gonzalez, FJ ;
Huang, JD ;
Idle, JR ;
IngelmanSundberg, M ;
Ishizaki, T ;
JacqzAigrain, E ;
Meyer, UA ;
Nebert, DW ;
Steen, VM ;
Wolf, CR ;
Zanger, UM .
PHARMACOGENETICS, 1996, 6 (03) :193-201
[8]   INVITRO FORECASTING OF DRUGS THAT MAY INTERFERE WITH CODEINE BIOACTIVATION [J].
DAYER, P ;
DESMEULES, J ;
STRIBERNI, R .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1992, 17 (02) :115-120
[9]   In silico methods for predicting ligand binding determinants of cytochromes P450 [J].
de Groot, MJ ;
Kirton, SB ;
Sutcliffe, MJ .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (16) :1803-1824
[10]   EVIDENCE THAT ASPARTIC-ACID-301 IS A CRITICAL SUBSTRATE-CONTACT RESIDUE IN THE ACTIVE-SITE OF CYTOCHROME-P450 2D6 [J].
ELLIS, SW ;
HAYHURST, GP ;
SMITH, G ;
LIGHTFOOT, T ;
WONG, MMS ;
SIMULA, AP ;
ACKLAND, MJ ;
STERNBERG, MJE ;
LENNARD, MS ;
TUCKER, GT ;
WOLF, CR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (49) :29055-29058